29 results on '"Hellmis E"'
Search Results
2. T-Rex-Studie: Real-world Evidenz und patient-reported Outcomes von mRCC-Patienten, die in der Erstlinie mit Tivozanib behandelt wurden
Catalog
Books, media, physical & digital resources
3. d-uo Versorgungsstudie zur Therapie des knochenmetastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) mit Radium-223: Daten einer retrospektiven Befragung
4. DAROL: Beobachtungsstudie zu Darolutamid bei Patienten mit nichtmetastasiertem, kastrationsresistentem Prostatakarzinom (nmCRPC)
5. 679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)
6. NIVOSWITCH : Phase II trial investigating nivolumab maintenance after TKI induction in metastatic renal cell carcinoma (mRCC) ; final results on efficacy and patient reported outcomes (PRO)
7. Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)
8. 1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
9. Randomized phase II trial comparing switch to nivolumab with TKI continuation after TKI induction for 12 weeks in metastatic renal cell carcinoma patients (NIVOSWITCH)
10. A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
11. Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
12. Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
13. PROfound: A randomized phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration
14. 959P - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
15. 1035 - Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
16. 810P - Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
17. Lycopene inhibits disease progression in patients with benign prostate hyperplasia
18. PROPIVERINE COMPARED TO OXYBUTYNIN IN CHILDREN WITH IDIOPATHIC DETRUSOR OVERACTIVITY – ARE EFFICACY AND TOLERABILITY COMPARABLE?
19. Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
20. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
21. [Prostate Cancer: Side-Effect Management for Androgen Deprivation Therapy].
22. [Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program].
23. [Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride].
24. LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
25. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
26. [Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis].
27. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
28. Sexual problems in males with epilepsy--an interdisciplinary challenge!
29. Lycopene inhibits disease progression in patients with benign prostate hyperplasia.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.